Harnessing novel strategies and cell types to overcome immune tolerance during adoptive cell therapy in cancer

J Immunother Cancer. 2023 Apr;11(4):e006434. doi: 10.1136/jitc-2022-006434.

Abstract

Cell therapy encompasses an expanding spectrum of cell-based regimes for the treatment of human ailments, such as the use of immune cells, in particular T cells, for combating tumors and the modulation of inflammatory immune responses. In this review, we focus on cell therapy in the immuno-oncology space, which is largely driven by interests and demands from the clinics for better solutions to target various hard-to-treat cancers. We discuss recent advances in various types of cell therapies, including T cell receptor-T cells, chimeric antigen receptor (CAR)-T cells, tumor-infiltrating lymphocytes and natural killer cells. Particularly, the present review focuses on the strategies to improve therapeutic responses by either enhancing tumor recognition or the resilience of infused immune cells within tumor microenvironment. Finally, we discuss the potential of other innate or innate-like immune cell types currently being explored as promising CAR-cell alternatives that seek to address the limitations of conventional adoptive cell therapies.

Keywords: adoptive; cell engineering; chimeric antigen; immunotherapy; killer cells; lymphocytes; natural; receptors; tumor-infiltrating.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell- and Tissue-Based Therapy
  • Humans
  • Immune Tolerance
  • Immunotherapy, Adoptive*
  • Neoplasms*
  • T-Lymphocytes
  • Tumor Microenvironment